Who is at risk for weight gain after weight-gain associated treatment with antipsychotics, antidepressants, and mood stabilizers: A machine learning approach.
antidepressants
antipsychotics
mood‐stabilizer
predictor
weight gain
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
revised:
05
03
2024
received:
02
10
2023
accepted:
20
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
Weight gain is a common side effect in psychopharmacology; however, targeted therapeutic interventions and prevention strategies are currently absent in day-to-day clinical practice. To promote the development of such strategies, the identification of factors indicative of patients at risk is essential. In this study, we developed a transdiagnostic model using and comparing decision tree classifiers, logistic regression, XGboost, and a support vector machine to predict weight gain of ≥5% of body weight during the first 4 weeks of treatment with psychotropic drugs associated with weight gain in 103 psychiatric inpatients. We included established variables from the literature as well as an extended set with additional clinical variables and questionnaires. Baseline BMI, premorbid BMI, and age are known risk factors and were confirmed by our models. Additionally, waist circumference has emerged as a new and significant risk factor. Eating behavior next to blood glucose were found as additional potential predictor that may underlie therapeutic interventions and could be used for preventive strategies in a cohort at risk for psychotropics induced weight gain (PIWG). Our models validate existing findings and further uncover previously unknown modifiable factors, such as eating behavior and blood glucose, which can be used as targets for preventive strategies. These findings underscore the imperative for continued research in this domain to establish effective preventive measures for individuals undergoing psychotropic drug treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Weight gain is a common side effect in psychopharmacology; however, targeted therapeutic interventions and prevention strategies are currently absent in day-to-day clinical practice. To promote the development of such strategies, the identification of factors indicative of patients at risk is essential.
METHODS
METHODS
In this study, we developed a transdiagnostic model using and comparing decision tree classifiers, logistic regression, XGboost, and a support vector machine to predict weight gain of ≥5% of body weight during the first 4 weeks of treatment with psychotropic drugs associated with weight gain in 103 psychiatric inpatients. We included established variables from the literature as well as an extended set with additional clinical variables and questionnaires.
RESULTS
RESULTS
Baseline BMI, premorbid BMI, and age are known risk factors and were confirmed by our models. Additionally, waist circumference has emerged as a new and significant risk factor. Eating behavior next to blood glucose were found as additional potential predictor that may underlie therapeutic interventions and could be used for preventive strategies in a cohort at risk for psychotropics induced weight gain (PIWG).
CONCLUSION
CONCLUSIONS
Our models validate existing findings and further uncover previously unknown modifiable factors, such as eating behavior and blood glucose, which can be used as targets for preventive strategies. These findings underscore the imperative for continued research in this domain to establish effective preventive measures for individuals undergoing psychotropic drug treatments.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.
Références
Dent R, Blackmore A, Peterson J, et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One. 2012;7(6):e36889. doi:10.1371/journal.pone.0036889
Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73‐96. doi:10.1517/14740338.2015.974549
Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta‐analysis. Lancet Psychiatry. 2020;7(1):64‐77. doi:10.1016/s2215‐0366(19)30416‐x
Seifert J, Engel RR, Bernegger X, et al. Time trends in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001‐2017. J Affect Disord. 2021;281:547‐556. doi:10.1016/j.jad.2020.12.073
Maher AR, Theodore G. Summary of the comparative effectiveness review on off‐label use of atypical antipsychotics. J Manag Care Pharm. 2012;18(5 Supp B):1‐20. doi:10.18553/jmcp.2012.18.s5‐b.1
Schneider J, Patterson M, Jimenez XF. Beyond depression: other uses for tricyclic antidepressants. Cleve Clin J Med. 2019;86(12):807‐814. doi:10.3949/ccjm.86a.19005
Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119‐136. doi:10.1002/wps.20204
Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta‐analysis. JAMA Psychiatry. 2015;72(4):334‐341. doi:10.1001/jamapsychiatry.2014.2502
Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, De Silva V. Antipsychotic‐associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231‐2241. doi:10.2147/ndt.s113099
Alvarez‐Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta‐analysis of longitudinal studies. Schizophr Res. 2012;139(1–3):116‐128. doi:10.1016/j.schres.2012.05.007
Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics‐induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol. 2019;844:231‐240. doi:10.1016/j.ejphar.2018.12.003
Asmar KE, Fève B, Colle R, et al. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: findings from the METADAP cohort. J Affect Disord. 2018;241:22‐28. doi:10.1016/j.jad.2018.07.059
Vandenberghe F, Gholam‐Rezaee M, Saigí‐Morgui N, et al. Importance of early weight changes to predict long‐term weight gain during psychotropic drug treatment. J Clin Psychiatry. 2015;76(11):e1417‐e1423. doi:10.4088/JCP.14m09358
De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412‐424. doi:10.1016/j.eurpsy.2009.01.005
Speyer H, Westergaard C, Albert N, et al. Reversibility of antipsychotic‐induced weight gain: a systematic review and meta‐analysis. Front Endocrinol. 2021;12:577919. doi:10.3389/fendo.2021.577919
Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight‐gain caused by antipsychotics: a systematic review and meta‐analysis. Expert Opin Drug Saf. 2020a;19(3):295‐314. doi:10.1080/14740338.2020.1713091
De Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta‐analysis. BMC Psychiatry. 2016;16(1):341. doi:10.1186/s12888‐016‐1049‐5
Lee S, Kim Y, Han M. Influence of waist circumference measurement site on visceral fat and metabolic risk in youth. J Obes Metab Syndr. 2022;31(4):296‐302. doi:10.7570/jomes22046
Leitliniengruppe DEVFD. S3‐Leitlinie Schizophrenie. Langfassung. Accessed October 7, 2019 2019 https://www.awmf.org/leitlinien/detail/ll/038-009.htmlx
Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. Effectiveness and cost‐effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act. 2011;8(1):28. doi:10.1186/1479‐5868‐8‐28
Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second‐generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 2006;29(7):587‐598. doi:10.2165/00002018‐200629070‐00004
Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004;30(2):229‐240. doi:10.1093/oxfordjournals.schbul.a007074
Gebhardt S, Haberhausen M, Heinzel‐Gutenbrunner M, et al. Antipsychotic‐induced body weight gain: predictors and a systematic categorization of the long‐term weight course. J Psychiatr Res. 2009;43(6):620‐626. doi:10.1016/j.jpsychires.2008.11.001
Chiliza B, Asmal L, Oosthuizen P, et al. Changes in body mass and metabolic profiles in patients with first‐episode schizophrenia treated for 12 months with a first‐generation antipsychotic. Eur Psychiatry. 2015;30(2):277‐283. doi:10.1016/j.eurpsy.2014.11.013
Kloiber S, Domschke K, Ising M, et al. Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. J Clin Psychiatry. 2015;76(6):e802‐e808. doi:10.4088/JCP.14m09212
Liu YT, Chau YL, Hsu SC, Chu CL, Chen CY. Factors influencing weight gain in an Asian population of psychiatric inpatients: a retrospective study in Taiwan. Asia Pac Psychiatry. 2014;6(2):226‐234. doi:10.1111/j.1758‐5872.2012.00223.x
Harrison RNS, Gaughran F, Murray RM, et al. Development of multivariable models to predict change in body mass index within a clinical trial population of psychotic individuals. Sci Rep. 2017;7(1):14738. doi:10.1038/s41598‐017‐15137‐7
Benarroch L, Kowalchuk C, Wilson V, et al. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology. 2016;233(14):2629‐2653. doi:10.1007/s00213‐016‐4324‐8
Case M, Treuer T, Karagianis J, Hoffmann VP. The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry. 2010;10:72. doi:10.1186/1471‐244x‐10‐72
Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ. Predictors and correlates for weight changes in patients co‐treated with olanzapine and weight mitigating agents; a post‐hoc analysis. BMC Psychiatry. 2009;9(1):12. doi:10.1186/1471‐244x‐9‐12
Garriga M, Mallorquí A, Serrano L, et al. Food craving and consumption evolution in patients starting treatment with clozapine. Psychopharmacology. 2019;236(11):3317‐3327. doi:10.1007/s00213‐019‐05291‐3
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta‐analysis. PLoS One. 2014;9(4):e94112. doi:10.1371/journal.pone.0094112
Kálmán J, Burkhardt G, Pogarell O, Padberg F, Schulze T, Falkai P. Integration of real‐world clinical data into the Munich mental health biobank – clinical and scientific potential and challenges. Eur Psychiatry. 2022;65(S1):S568‐S568. doi:10.1192/j.eurpsy.2022.1455
World Health Organization. WHO STEP wise Approach to Surveillance (STEPS). 2008.
Simon MS, Barton BB, Glocker C, Musil R. A comprehensive approach to predicting weight gain and therapy response in psychopharmacologically treated major depressed patients: a cohort study protocol. PLoS One. 2022;17(7):e0271793. doi:10.1371/journal.pone.0271793
Pudel V, Westhöfer J. Fragebogen zum Essverhalten (FEV). Verlag für Psychologie Dr. C. J. Hogrefe; 1991.
Stunkard AJ, Messick S. The three‐factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71‐83. doi:10.1016/0022‐3999(85)90010‐8
White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and validation of the food‐craving inventory. Obes Res. 2002;10(2):107‐114. doi:10.1038/oby.2002.17
McFadden D. Quantitative Methods for Analyzing Travel Behaviour of Individuals: Some Recent Developments. 1977 https://EconPapers.repec.org/RePEc:cwl:cwldpp:474
Charbuty B, Abdulazeez AM. Classification based on decision tree algorithm for machine learning. J Appl Sci Technol Trend. 2021;2:20‐28.
Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit‐learn: machine learning in python. J Mach Learn Res. 2011;12:2825‐2830.
Hemmert G, Edinger‐Schons L, Wieseke J, Schimmelpfennig H. Log‐likelihood‐based pseudo‐R2 in logistic regression: deriving sample‐sensitive benchmarks. Sociol Methods Res. 2016;47:507‐531. doi:10.1177/0049124116638107
Glocker G, Simon MS, Adler N, Eder J, Barton BB, Musil R. Development and evaluation of the “Eating more consciously” module of a lifestyle intervention program to prevent medication‐induced Weight Gain: A one arm pilot study. Submitted.
Bryant EJ, King NA, Blundell JE. Disinhibition: its effects on appetite and weight regulation. Obes Rev. 2007;9(5):409‐419. doi:10.1111/j.1467‐789x.2007.00426.x
Firth J, Teasdale SB, Jackson SE, et al. Do reductions in ghrelin contribute towards antipsychotic‐induced weight gain? Schizophr Res. 2019;210:301‐302. doi:10.1016/j.schres.2018.12.043
Reents J, Seidel AK, Wiesner CD, Pedersen A. The effect of hunger and satiety on mood‐related food craving. Front Psychol. 2020;11:568908. doi:10.3389/fpsyg.2020.568908
Anghelescu I, Klawe C, Szegedi A. Add‐on combination and maintenance treatment: case series of five obese patients with different eating behavior. J Clin Psychopharmacol. 2002;22(5):521‐524. doi:10.1097/00004714‐200210000‐00014
Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic‐induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185‐193. doi:10.1001/jama.2007.56‐b
Barton BB, Zagler A, Engl K, Rihs L, Musil R. Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the metabolism in psychiatry (MiP) study. Eur Arch Psychiatry Clin Neurosci. 2020b;270(5):597‐609. doi:10.1007/s00406‐019‐01043‐8